Galena Biopharma Inc (NASDAQ:GALE), Idera Pharmaceuticals Inc (NASDAQ:IDRA) and BioDelivery Sciences International, Inc. (NASDAQ:BDSI) all released their earnings reports for 4Q2015. While GALE and IDRA reported a loss for their 4Q2015, BDSI was able to report a net income, after having a net loss for 4Q2014. Similarly, GALE and BDSI missed analyst expectations, for their EPS, while IDRA was able to beat analyst expectations.
Galena Biopharma reported a total loss of $19.7 million, during its 4Q2015, resulting in a negative EPS of $0.12. As such, the company’s EPS for FY2015 reached -$0.41 or $63.9 million. Mark W. Schwartz, the CEO of GALE, highlighted two upcoming milestones for FY2016. These concern the phase-3 clinical trials of NeuVax. The drug is targeted at the prevention of recurring breast cancer. The announcement resulted in Galena Biopharma Inc (NASDAQ:GALE) shares losing 6.76% of their value, during the March 10 session, to reach a close at $0.886.
Similarly, Idera Pharmaceuticals reported $12 million in losses, during the 4Q2015. The EPS for the quarter stood at -$0.1. For its FY2015, the company had revenues of $249,000 and a loss of $48.6 million, resulting EPS for the year to fall to -$0.42. The highlights of the quarter included the signing of a collaboration and license agreement with GSK. The agreement concerns 3rd Generation Antisense molecules for treatment of renal diseases. Idera Pharmaceuticals Inc (NASDAQ:IDRA) lost 4.81% in terms of its share value, after the announcement, to close at $1.78, at the end of the March 10 trading session.
BioDelivery Sciences was the only one, of the three pharmaceutical companies, to report a net-income for the quarter. The income for 4Q2015 stood at $10.2 million or an EPS of $0.2. The revenue for 4Q2015 stood at $32.2 million. Dr. Mark A. Sirgo, the CEO of BDSI, stated during FY2016, the company would enhance its sales team. This would be assisted by agreement with Tennessee Medicaid and certain government driven initiatives. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) also lost some of its share value, 8.11%, during the March 10 trading session, to close at $3.40.